Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Trends-2030


This 194-page report, “Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Region,” is highlighted by 96 tables and 86 figures and is based on extensive research of the entire global pharmaceutical CDMO market and all of its sub-segments through extremely detailed classifications. Premium primary and secondary information sources are used to create in-depth research and assessment, with input coming from business specialists working across the value chain.

The market for pharmaceutical CDMOs will reach $289.2 billion by 2030, growing at a 6.9% annual rate from 2020 to 2030 because to rising demand for specialised drugs and biological therapies, increased need to keep drug development costs under control, and rising healthcare costs.

The research uses 2019 as the foundation year for its estimate, which ranges from 2020 to 2030 and is based on studies from 2015 to 2019. (Please note that the report will be updated before to delivery to ensure that the forecast includes at least 5 years past the base year and the most recent historical year serves as the base year.)

Request Research Sample with Latest Industry Insights (190+ Pages Report):

The following aspects are identified and examined in-depth qualitative analyses:

• Market Organization
• Growth Agents
• Challenges and Restrictions
• Market Opportunities & Emerging Product Trends
• Fiver Forces Porter

By taking COVID-19 into consideration, the trend and outlook for the global market are predicted with an upbeat, fair-minded, and conservative viewpoint. The global pharmaceutical CDMO market is quantified from the standpoints of Category, Service Type, Therapeutic Application, End User, and Region using the balanced (most likely) forecast.

The global market is divided into the following sub-markets according to category, with annual revenue for 2019–2030 mentioned in each area.

• Pharmaceutical Industry
• Biopharmaceutical Industry

Based on Service Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Pharmaceutical Contract Manufacturing Organization (CMO)

• Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
• Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
• Secondary Packaging

Pharmaceutical Contract Research Organization (CRO)

• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services

Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria,Ireland, Norway, Denmark, and Finland)

• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, South Africa)

There are thorough analyses and data for annual revenue for each of the aforementioned regions and nations for the years 2019 through 2030. There is also a breakdown of the major national markets by Category, Service Type, and Therapeutic Application during the anticipated years, as well as a breakdown of the regional markets by country.

The study also analyses the present competition landscape, the anticipated trend, and it provides profiles of key vendors, including both established market leaders and significant up-and-coming companies.
Through GMD’s Risk Assessment System, possible risks related to investments in the worldwide pharmaceutical CDMO industry are specifically assessed quantitatively and qualitatively. Critical Success Factors (CSFs) are developed based on the risk analysis and evaluation as a guide to assist investors and stockholders in identifying emerging possibilities, managing and minimising risks, developing suitable business models, and making informed strategies and decisions.

Key Players (this list may not be exhaustive; additional businesses can be included upon request):

Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.